The investigators hypothesize:~Use of oral systemic antibiotic treatment with dicloxacillin (1000 mg x 3 times a day) will decrease the time to AD improvement as well as the amount of S. aureus and its toxins and alter the skin microbiome.~Specifically, the investigators aim to investigate the following research questions:~RQ1: Does the addition of systemic dicloxacillin to TCS treatment result in a more rapid and deeper treatment response?~RQ2: Does the addition of systemic dicloxacillin to TCS treatment affect the skin microbiome, the skin barrier and immune response during improvement of AD?~RQ3: Does topical application of S. aureus or SEB increase the severity and rapidity of a flare?~RQ4: Does topical application of S. aureus and SEB alter the skin microbiome, the skin barrier and immune response during a flare of AD?~RQ5: Can changes in protein expression or metabolic pathways explain the modulated mechanisms in the host-microbial cross talk of AD?
The goal of this clinical trial is to compare and evaluate in patients with atopic dermatitis. The main questions it aims to answer are:~Does the addition of systemic dicloxacillin to TCS treatment result in a more rapid and deeper treatment response?~Does the addition of systemic dicloxacillin to TCS treatment affect the skin microbiome, the skin barrier and immune response during improvement of AD?~Does topical application of S. aureus or SEB increase the severity and rapidity of a flare?~Participants will meet for two different phases:~Phase one will be at randomized controlled trial where patients are randomized to either systemic dicloxacillin + mometasone furoate or placebo + mometasone furoate.~Phase II: Patients will meet for five visits to receive different solutions on the skin including autologous s. aureus and staphylococcal enterotoxin B.